1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Nutranomics, Inc.

Nutranomics, Inc.

NNRX
Nutranomics, Inc.US flagOther OTC
0.00
USD
- -
- -
816,232.00Market Cap
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2014 Y
2015 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
0.05
0.02
0.01
Basic EPS, GAAP
- -
- -
- -
- -
- -
-0.05
-0.01
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
-0.01
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
-0.1
-0.05
-0.03
Tangible Book Value per Share
- -
- -
- -
- -
- -
-0.03
-0.01
-0.01
Basic Weighted Avg Shares
46
46
46
46
46
46
112
236
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
2
2
2
Operating Margin (%)
- -
- -
- -
- -
- -
-79.8
-46.73
-78.49
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
-2
-1
-2
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
-90.41
-68.04
-131.77
Working Capital
- -
- -
- -
- -
- -
-1
-1
-2
LT Debt
- -
- -
- -
- -
- -
1
- -
- -
Total Equity
- -
- -
- -
- -
- -
-1
-1
-2
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Apr'15
Jul'15
Oct'16
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
161
252
532
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Apr'15
Jul'15
Oct'16
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
2
3
Payables & Accruals
1
1
1
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-1,530.87%
6.37%
Free Cash Flow
- -
501.07%
-32.12%
Net Income, GAAP
- -
1,814.55%
-43.95%
Sales/Revenue/Turnover
- -
- -
-25.53%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
- -
1
- -
1
2
2015
1
- -
- -
- -
2
2016
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
-0.02
-0.01
- -
-0.01
-0.05
2015
- -
-0.02
- -
- -
-0.01
2016
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Jonathan Bishop
Full Time Employees
1
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
11487 South 700 East Salt Lake City UT United States of America 84020
IPO Date
Apr 16, 2013
CIK
0001451433
Website
nutranomics.com
Similar Companies
Lifeist Wellness Inc. (LFST.V)
Glenmark Life Sciences Limited (GLS.NS)
Ventura Cannabis & Wellness Corporation (CVHIF)
Aurora Cannabis Inc. R (21P.F)
Anhui Fengyuan Pharmaceutical Co., Ltd. (000153.SZ)
Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SS)
Business
Nutranomics, Inc. (NNRX) engages in the research, development, sale, and distribution of nutritional food products, specializing in formulated nutritional supplements including vitamins, minerals, herbals, and probiotics; it offers approximately 480 such supplements alongside diagnostic tools like Nutritional Blood Analysis for real-time examination of blood cells on video monitors and the patented Assimilation Enhancing System to enhance nutrient absorption; additionally, the company provides educational services encompassing analyses, trainings, certifications, and group presentations for individuals and industry professionals. Founded in 1995 and headquartered in Salt Lake City, Utah, Nutranomics operates primarily in the healthcare sector under drug manufacturers—specialty and generic—with distribution through sales representatives and retail stores across North America and Asia, including countries such as the USA, Canada, Taiwan, Japan, Singapore, Philippines, and Malaysia; it maintains a strategic partnership with Terra-Formance, LLC, and key executives include CEO Jonathan Bishop, President and Chief Revenue Officer Geoffrey Bazegian, and Chief Operations Officer Laura Riffel. Among its recent major developments, Nutranomics completed the acquisition of DHS Development, Inc. dba The Plant in 2022, committing $6.5 million in capital over 12 months to bolster manufacturing, packaging, extraction, processing, and product development capabilities, particularly for cannabis-related products, which drove record topline growth in the initial post-acquisition period and positioned the company for expanded retail-ready solutions and future mergers.